Oncotarget is an online peer-reviewed medical journal. It is published on a weekly basis and provides free access. It was in 2010 that Oncotarget was launched by Dr. Mikhail Blagosklonny and Dr. Adnrei V. Gudkov, and it is published by Impact Journals. Dr. Blagosklonny and Dr. Gudkov serve Oncotarget as co-editors-in-chief, both of whom work at the Roswell Park Cancer Institute in Buffalo, New York.
While primarily focused on the field of Oncology, Oncotarget accepts and publishes papers from a number of fields of medicine including Metabolism, Endocrinology, Neuroscience, and Pharmacology. Its 5-year impact factor is 5.415 as papers published in Oncotarget are regularly cited in other research papers. Oncotarget has also ranked Q1 (which is the highest rank) by Scopus/SJR and has achieved that ranking every year since 2011. Read more about Oncotarget at Bioxbio.
The mission of Oncotarget is to make the research papers it publishes rapidly and widely available. The journal was also established in order to help eliminate the boundaries between different medical specialties. It also seeks to combine different specialties together in order to foster new scientific discoveries and advances as well fight diseases and find cures.
In addition to Dr. Gudkov and Dr. Blagosklonny, the founding editorial board of Oncotarget is made up of over 40 scientists across the world. These scientists work at hospitals, research institutes, and universities including John Hopkins University School of Medicine, Standford University School of Medicine, Harvard Medical School, The Scripps Research Institute, and Children’s Hospital of Pittsburg among others.
Oncotarget follows the COPE Code of Conduct and Best Practices Guidelines for Journal Editors. It also follows the Code of Conduct for Journal Publishers. The authors, editors, and reviewers must also follow best-practice guidelines in regards to ethical behavior. These guidelines follow the ICMJE’s recommendations.